Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDSupernus Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | $0.34 | $0.40 | $0.37 |
| Q2 2025 | 2 | $0.41 | $0.53 | $0.47 |
| Q3 2025 | 3 | $0.24 | $1.09 | $0.59 |
| Q4 2025 | 2 | $0.28 | $0.49 | $0.39 |
| Q1 2026 | 1 | $0.36 | $0.40 | $0.38 |
| Q2 2026 | 1 | $0.55 | $0.60 | $0.58 |
| Q3 2026 | 1 | $0.75 | $0.82 | $0.79 |
| Q4 2026 | 1 | $0.92 | $1.00 | $0.96 |
Supernus Pharmaceuticals, Inc. Earnings Date And Information
Supernus Pharmaceuticals, Inc. last posted its earnings results on Tuesday, November 4th, 2025. The company reported $1.01 earnings per share for the quarter, topping analysts' consensus estimates of $0.82 by $0.19. The company had revenue of 192.10 M for the quarter and had revenue of 661.82 M for the year. Supernus Pharmaceuticals, Inc. has generated $1 earnings per share over the last year ($1.32 diluted earnings per share) and currently has a price-to-earnings ratio of -134.36. Supernus Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 3rd, 2025 based on prior year's report dates.
Supernus Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2025 | Q3 2025 | N/A | -$0.80 | N/A | $180.22 M | $192.10 M |
| 08/05/2025 | Q2 2025 | $0.47 | $0.40 | -0.07 | $154.06 M | $165.45 M |
| 05/06/2025 | Q1 2025 | $0.38 | -$0.21 | -0.59 | N/A | $149.82 M |
| 02/25/2025 | Q4 2024 | $0.46 | $0.28 | -0.18 | N/A | $174.16 M |
| 11/04/2024 | Q3 2024 | $0.39 | $0.70 | 0.31 | $157.35 M | $175.69 M |
| 08/06/2024 | Q2 2024 | $0.31 | $0.36 | 0.05 | $148.83 M | $168.33 M |
| 05/08/2024 | Q1 2024 | $0.38 | $0.00 | N/A | N/A | $143.64 M |
| 02/27/2024 | Q4 2023 | $0.41 | $0.02 | -0.39 | N/A | $164.31 M |
| 11/08/2023 | Q3 2023 | $0.13 | -$0.29 | -0.42 | $146.17 M | $153.88 M |
| 08/08/2023 | Q2 2023 | $0.23 | -$0.02 | -0.25 | $143.63 M | $135.56 M |
| 05/09/2023 | Q1 2023 | $0.17 | $0.31 | 0.14 | $139.02 M | $153.76 M |
| 03/09/2023 | Q4 2022 | N/A | $0.47 | N/A | $180.33 M | $167.33 M |
| 11/09/2022 | Q3 2022 | N/A | $0.03 | N/A | $172.48 M | $177.35 M |
| 08/08/2022 | Q2 2022 | N/A | $0.15 | N/A | $164.13 M | $170.05 M |
| 05/12/2022 | Q1 2022 | N/A | $0.48 | N/A | $153.91 M | $152.51 M |
| 04/13/2022 | Q4 2021 | $0.24 | $0.05 | -0.19 | $155.00 M | $159.05 M |
| 11/05/2021 | Q3 2021 | N/A | $0.41 | N/A | $142.12 M | $148.46 M |
| 08/06/2021 | Q2 2021 | N/A | $0.45 | N/A | $135.42 M | $141.33 M |
| 05/07/2021 | Q1 2021 | N/A | $0.11 | N/A | $129.10 M | $130.93 M |
| 03/08/2021 | Q4 2020 | N/A | $0.58 | N/A | $146.19 M | $143.56 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Supernus Pharmaceuticals, Inc. Earnings: FAQ's
Supernus Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 3rd, 2025 based offlast year's report dates.
In the previous quarter, Supernus Pharmaceuticals, Inc. (:SUPN) reported $1.01 earnings per share (EPS) to beat the analysts' consensus estimate of $0.82 by $0.19.
The conference call for Supernus Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Supernus Pharmaceuticals, Inc.'s latest earnings report can be read online.
Supernus Pharmaceuticals, Inc. (:SUPN) has a recorded annual revenue of $661.82 M.
Supernus Pharmaceuticals, Inc. (:SUPN) has a recorded net income of $73.87 M.Supernus Pharmaceuticals, Inc. has generated $1.34 earnings per share over the last four quarters.
Supernus Pharmaceuticals, Inc. (:SUPN) has a price-to-earnings ratio of -134.36 and price/earnings-to-growth ratio is 1.05.